The Patent Finder

Arcus Biosciences, Inc.

40 patents currently held · Updated Nov 16, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Jan 2037
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 6, 2026
    The maintenance fee for Modulators of 5'-Nucleotidase, Ecto and the Use Thereof (US 11,667,662) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
  • 1 fee due Mar 3, 2027
    The maintenance fee for Azolopyrimidine for the Treatment of Cancer-Related Disorders (US 10,399,962) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
  • 1 fee due Apr 17, 2027
    The maintenance fee for Tetralin and Tetrahydroquinoline Compounds as Inhibitors of HIF-2ALPHA (US 11,787,762) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
  • 2 fees due May 21, 2027
  • 1 fee due Sep 19, 2027
    The maintenance fee for CD73 inhibitors (US 11,931,343) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,239,912Modulators of 5'-Nucleotidase, Ecto and the Use Thereof
In force
 · High confidence
In forceHigh confidence
US 10,981,944Modulators of 5'-Nucleotidase, Ecto and the Use Thereof
In force
 · High confidence
In forceHigh confidence
US 11,001,603Modulators of 5'-Nucleotidase, Ecto and the Use Thereof
In force
 · Low confidence
In forceLow confidence
US 11,667,662Modulators of 5'-Nucleotidase, Ecto and the Use Thereof
In force
 · Low confidence
In forceLow confidence
US 12,459,967Modulators of 5'-Nucleotidase, Ecto and the Use Thereof
In force
 · Low confidence
In forceLow confidence
US 11,058,704Inhibitors of adenosine 5′-nucleotidase
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,168,023Inhibitors of adenosine 5′-nucleotidase
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,267,845Inhibitors of CD73-mediated immunosuppression
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,399,962Azolopyrimidine for the Treatment of Cancer-Related Disorders
In force
 · High confidence
In forceHigh confidence
US 11,072,597Azolopyrimidine for the Treatment of Cancer-Related Disorders
In force
 · High confidence
In forceHigh confidence
10 of 40 patents shown.
Pro members see all 40.
Pro members: see all 40 patents
Also on record, not counted in the 40: 1 patent in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

13 pending · 2 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited